Gastrointestinal effects of COX-2 inhibitors

Bibliography

• WALT R, KATCHINSKI B, LOGAN R et al.: Rising frequency of ulcer perforation in elderly people in the United Kingdom. Lancet (1986) 2:489–492.
   PubMedGoogle Scholar
• DOUTHWAITE A, LINTOT CA: Gastroscopic observa-tions of the effect of aspirin and certain other substances on the stomach. Lancet (1938) 2:1222–1225.
   Google Scholar
• SUN DC, ROTH SH, MITCHELL CS, ENGLUND DW: Upper gastrointestinal disease in rheumatoid arthritis. Am. J. Dig Dis. (1974) 19:405–410.
   PubMedGoogle Scholar
• VANE JR: Inhibition of prostaglandin synthesis as amechanism of action for the aspirin-like drugs. Nature New Biol. (1971) 231:232–235.
   PubMedGoogle Scholar
• FLOWER RJ, VANE JR: Inhibition of prostaglandinsyntethase in brain explains the antipyretic activity of paracetomol (4-acetamide -phenol) . Nature (1972) 120:412–421.
   Google Scholar
• FU JY, MASFERRER JL, SEIBERT K, RAZ A, NEEDLEMANN P: The induction and suppression of prostaglandin 112 Synthase (cyclooxygenase) in human monocytes. J. Biol. Chem. (1990) 265:16737–16740.
   PubMed Web of Science ®Google Scholar
• ••Key developmental paper.
   Google Scholar
• KUJUBU DA, FLETCHER BS, VARNUM BC, LIM RW, HERSCHMANN HR: TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxyge-nase homologue. J. Biol. Chem. (1991) 266:12866–12872.
   PubMed Web of Science ®Google Scholar
• ••Key developmental paper.
   Google Scholar
• VANE JR, MITCHELL JA, APPLETON I et al.: Inducibleisoforms of cyclooxygenase and nitric oxide synthase in inflammation. Proc. Natl. Acad. ScL USA (1994) 91:2046–2050.
   PubMed Web of Science ®Google Scholar
• KARGAN S, CHARLESON S, CARTWRIGHT M et al.:Characterization of prostaglandin G/H synthase 1 and 2 in rat, monkey and human gastrointestinal tract. Gastroenterology (1996) 111:445–454.
   PubMed Web of Science ®Google Scholar
• FELLOWS IW, BHASKAR NK, HAWKEY CJ: The nature andtime course of piroxicam induced injury to human gastric mucosa. Aliment. Pharmacol. Therap. (1989) 3:481–488.
   PubMed Web of Science ®Google Scholar
• HAWKEY CJ, HUDSON N: Mucosal Injury caused by drugs, chemicals and stress. In: Bockus gastroenterology, 5th edition, vol. 2. Haubrich WS, Schaffner F, Berck JE, (Eds.), WB Saunders, Philadelphia, USA (1994):656–699.
   Google Scholar
• •Comprehensive review of gastrointestinal defence system.
   Google Scholar
• HAWKEY CJ: Non steroidal anti-inflammatory drugsand peptic ulcers. Facts and Figures multiply, but do they add up? BMJ (1990) 300:278–284.
   Google Scholar
• SATOH H, INADA I, HIRATA T, MAKI Y: Indomethacinproduces gastric antral ulcers in the refed rat. Gastro-enterology (1981) 81(4):719–725.
   PubMed Web of Science ®Google Scholar
• ALLISON MC, HOWATSON AG, TORRANCE CJ, LEE FD,RUSSELL RI: Gastrointestinal damage associated with the use of non steroidal anti-inflammatory drugs. New Eng. J. Med. (1992) 327(10:749–754.
   PubMedGoogle Scholar
• KAUFMAN HJ, TAULIN HL: Non steroidal anti-inflammatory drugs activate quiescent Inflamma-tory bowel disease. Ann. Intern. Med. (1987) 107:513–516.
   PubMed Web of Science ®Google Scholar
• HALL RI, PETTY AH, COBDEN I, LENDRUM R: Enteritisand colitis associated with mefanamic acid. BM/ (1983) 287:1182.
   PubMed Web of Science ®Google Scholar
• SOMASUDURAN S, HAYLLAR J, RAFI S et al.: Thebiochemical basis of NSAID-induced damage to the GI tract: a review and hypothesis. Scand. J. Gastroenterol (1995) 30:289–299.
   PubMed Web of Science ®Google Scholar
• SILVERSTEIN FE, GRAHAM DY, SENIOR JR et al.: Misoprostol reduces serious gastrointestinal compli-cations in patients with rheumatoid arthritis receiving non steroidal anti-inflammatory drugs. Ann. Intern. Med. (1995) 123(4):241–249.
   PubMed Web of Science ®Google Scholar
• •Looked at ulcer complication rate.
   Google Scholar
• PICOT D, LOLL PJ, GARAVITO RM: The X-ray crystal structure of the membrane protein prostaglandin 112 synthase-1. Nature (1994) 367:243–249.
   PubMed Web of Science ®Google Scholar
• LUONG C, MILLLER A, BARNETT J, CHOW J, RAMESHA C, BROWNER MF: The structure of human cyclooxygenase-2: Conservation and flexibility of the NSAID binding site. Nature Strucf Biol. (1996) 3:927–933.
   PubMedGoogle Scholar
• •Crystallography outlined.
   Google Scholar
• KURUMBAIL RG, STEVENS AM, GIERSE JK et al.: Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature (1996) 384: 644–648.
   PubMed Web of Science ®Google Scholar
• GIERSE J, MCDONALD J, HAUSER S, RANGWALA S, SEIBERT K: A single amino acid difference between cyclooxygenase-1 (COX-1) and -2 (COX-2) reverses the selectivity of COX-2 specific inhibitors. J. Biol. Chem. (1996) 271:15810–15814.
   PubMed Web of Science ®Google Scholar
• PAIRET M, VAN RYN J, MAUZ A et al.: Differential inhibi-tion of COX-1 and COX-2 by NSAIDs: A summary of results obtained using various test systems. In: Selective COX-2 Inhibitors. Pharmacology, Clinical Effects, and Therapeutic Potential. Sir J Vane and J Boning (Eds.), Kluwer Academic Publishers, Dordrecht/Boston/London (1997) 3:27–46.
   Google Scholar
• ••Reference paper looking at different systems used tomeasure COX-2 selectivity.
   Google Scholar
• PATRIGANI P, PANARA MR, GRECO A et al.: Biochemical and pharmacological characterisation of the cyclooxygenase activity of human blood prosta-glandin endoperoxide synthases. J. Pharm. Exp. Therap. (1994) 271:1705–1712.
   PubMed Web of Science ®Google Scholar
• PATRIGANI P, PANARA MR, SCIULLI MG, SANTINI G, RENDA G, PATRONO C: Differential inhibition of human prostaglandin endoperoxide synthase-1 and -2 by nonsteroidal anti-inflammatory drugs. J. Physiol. Pharmacol. (1997) 48(4):623–631.
   PubMed Web of Science ®Google Scholar
• NOBLE S, BALFOUR JA: Meloxicam. Drugs (1996)51:424–432.
   PubMed Web of Science ®Google Scholar
• GOEITHE HS, LUND B, DISTEL MR, BLUMKHI E: A double-blind, randomized trial to compare meloxicam 15 mg with diclofenac 100 mg in the treatment of osteoarthritis of the knee. Osteoarthritis Cartilage (1997) 15:283–288.
   Google Scholar
• LINDEN B, DISTEL M, BLUHMKI E: A double-blind study to compare the efficacy and safety of meloxicam 15 mg with piroxicam 20 mg in patients with osteoarthritis of the hip. Br. J. Rheumatol. (1996) 35 (Suppl. 0:35–38.
   Google Scholar
• HOSIE J, DISTEL M, BLUHMKI E: Meloxicam in osteoar-thritis: a six months, double-blind comparison with diclofenac sodium. Br. J. Rheumatol. (1996) 35 (Suppl. 1)39–43.
   Google Scholar
• HOSIE J, DISTEL M, BLUHMKI E Efficacy and tolerability of meloxicam versus piroxicam in patients with osteoarthritis of the hip or knee. A six-month double-blind study. Clin. Drug Invest. (1997) 13:175–184.
   Web of Science ®Google Scholar
• WOJTULEWSKI JA, SCHATTENKIRCHNER M, BARCELO P et al.: A six months double-blind trial to compare the efficacy and safety of meloxicam 7.5 mg daily and naproxen 750 mg daily in patients with rheumatoid arthritis. Br. J. Rheumatol (1996) 35 (Suppl. 1):22–28.
   Google Scholar
• PATOIA I, SANTUCCI I, FURNO P et al.: A four-week, double-blind, parallel-group study to compare the gastrointestinal effects of meloxicam 7.5 mg, meloxicam 15 mg, piroxicam 20 mg and placebo by means of faecal blood loss, endoxcopy and symptoms evaluation in healthy volunteer. Br. J. Rheumatol (1996) 35:61–67.
   Google Scholar
• DISTEL M, MUELLER C, BLUHMKI E et al: Global analysis of safety of a new NSAID, meloxicam. Br. J. Rheumatol (1996) 35 (Suppl. 0:68–77.
   Google Scholar
• HAWKEY C, KAHAN A, STEINBRUCK K et al.: Gastrointes-tinal tolerabability of the COX-2 inhibitor, Meloxicam, in osteoarthritis patients: The meloxicam large scale internatinal study safety assessment (MELISSA). Br. J. Rheumatol. (1998) 37:937–945.
   PubMedGoogle Scholar
• •Important study looking at more long-term use of meloxicam.
   Google Scholar
• DEQUEKER J, HAWKEY C, KAHAN A et al: Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the safety and efficacy large-scale evaluation of COX-inhibiting therapies (SELECT) trial in osteoarthritis. Br. J. Rheumatol. (1998) 37:946–951.
   PubMedGoogle Scholar
• •Complements MELISSA study above.
   Google Scholar
• DAVIS R, BROGDEN RN: Nimesulide. An update on its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs (1994) 48:431–454.
   Google Scholar
• TOFANETTI 0, CASCIARRI I, CIPOLLA PV, CAZZULANI P, OMINI C: Effect of nimesulide on cyclooxygenase activity in rat gastric mucosa and inflammatory exudate. Med. Sci. Res. (1989) 17:745–746.
   Google Scholar
• TAVARES IA, BISHAI PM, BENNETT A: Activity of nimesu-lide on constitutive and inducible cyclooxygenases. Arzneim Forsch/Drug Res. (1995) 45:1093–1095.
   PubMed Web of Science ®Google Scholar
• LAINE L, SLOANE R, FERRETTI M, CORNICELLI F: A randomised double blind comparision of placebo, etodolac, and naproxen on gastrointestinal injury and prostaglandin production. Gastrointest. Endoscop. (1995) 42:428–433.
   PubMed Web of Science ®Google Scholar
• EVERSMEYER W, POLAND M, DE LAPP RE, JENSEN CP: Safety experience with nambumetone versus naproxen, ibuprofen and piroxicam in osteoarthritis and rheumatoid arthritis. Am. J. Med. (1993) 95 (Suppl. 2a):10–18.
   Google Scholar
• RIENDEAU D, PERCIVAL MD, BOYCE S et al. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor. Br. J .Pharmacol. (1997)121:105–117.
   PubMed Web of Science ®Google Scholar
• CIPOLLONE F, GANCI A, PANARA MR, GRECO A, CUCCURULLO F, PATRONO C: Effects of nabumetone on prostanoid synthesis in humans. Clin. Pharmacol. Therap. (1995) 58:335–341.
   PubMed Web of Science ®Google Scholar
• Celecoxib. In: Pharma Projects CD ROM, Pharma BrooksLtd. (1998).
   Google Scholar
• PENNING TD, TALLEY JJ, BERTENSHAW SR et al.:Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibi-tors: Identification of 445-(4-methylphenyl) -3-(trifluoromethyl)-1H-pyrazol-1-y]benzenesulfona-mide (SC-58635, celecoxib). J. Med. Chem. (1997) 40(9) :1347–1365.
   PubMed Web of Science ®Google Scholar
• ISAKSON P, ZWEIFEL B, MASFERRER J et al: Specific COX-2 inhibitors: from bench to bedside. In: Selective COX-2 Inhibitors. Pharmacology, Clinical Effects, and Therapeutic Potential. Sir John Vane and Dr Jack Boning (Eds.), William Harvey Press. London (1997):127–133.
   Google Scholar
• LIPSKY PE, ISAKSON PC: Outcome of specific COX-2 inhibition in rheumatoid arthritis. J. Rheumatol. (1997) 24:9–14.
   PubMed Web of Science ®Google Scholar
• MENGLE-GAW L, HUBBARD RC, KARIM A et al.: A study ofthe platelet effects of SC-58635, a novel COX-2-selective inhibitor. Arthritis Rheum. (1997) 40\(Suppl. 9):S93.
   Google Scholar
• SIMON LS, LANZA FL,LIPSKY PE et al.: Preliminary studyof the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor. Efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arthritis Rheum. (1998) 41(9):1591–1602.
   Google Scholar
• •Evaluation of celecoxib.
   Google Scholar
• GEISS GS, STEAD H, MORANT SV, NAUDIN R, HUBBARDRC: Endoscopic and tolerability results from a study of celecoxib a specific COX-2 inhibitor, in patients with rheumatoid arthritis. Rheumatol Eur. (1998) 27 (Suppl. 1)118.
   Google Scholar
• GEISS GS, HUBBARD RC, CALLISON DA, YU S, ZHAO W:Safety and efficacy of celecoxib, a specific COX-2 inhibitor, in patients with rheumatoid arthritis. Rheumatol. Europe (1998) 27\(Suppl. 1):118.
   Google Scholar
• HUBBARD RC, GEISS GS, WOODS EM, YU JS, ZHAO W:Efficacy, tolerability, and safety of celecoxib, a specific COX-2 inhibitor, in osteoarthritis. Rheumatol. Europe (1998) 27 (Suppl. 0:118.
   Google Scholar
• GEIS GS, STEAD H, MORANT SV, NAUDIN R, HUBBARD RC: Endosocopic and tolerability results from a study of celecoxib, a specific COX-2 inhibitor, in rheumatoid arthritis. Rheumatol. Europe (1998) 27 (Suppl 1):118.
   Google Scholar
• LANZA FL, RACK MF, CALLISON et al.: A pilot endoscopic study of the gastroduodenal effects of SC-58635, a novel COX-2-selective inhibitor. Gastroenterology (1997) 112 (Suppl. 4):A194.
   Google Scholar
• EHRICH EW, DALLOB A, DE LEPELIERE et al.: Characteri-zation of rofexicob as a cyclooxygenase-2 isoform inhibitor and demonstration of analgaesia in dental pain model. Clin. Pharm. Ther. (1999) 65(3):336–348.
   PubMed Web of Science ®Google Scholar
• EHRICH E, MEHLISCH D, PERKINS S et al.: Efficacy of MK-966, a highly selective inhibitor of COX-2, in the treatment of postoperative dental pain. Arthritis Rheumatism (1996) 39 (Suppl. 9):S81.
   Google Scholar
• MEHLISCH DR, MILLS S, SANDLER M et al.: Ex vivo assay of COX-2 inhibition predicts analgesic efficacy in post-surgical dental pain with MK-966. Clin. Pharmacol Therap. (1998) 63(2):139.
   Web of Science ®Google Scholar
• SAAG K, FISHER C, McKAY J et al.: MK-0966, a specific COX-2 inhibitor, has clinical efficacy comparable to ibuprofen in the treatment of knee and hip osteoar-thritis (OA) in a six-week controlled clinical trial. Arthritis Rheumatism (1998) 41 (Suppl. 9)984.
   Google Scholar
• CANNON G, CALDWELL J, HOLT P et al.: MK-0966, a specific COX-2 inhibitor, has clinical efficacy comparable to diclofenac in the treatment of knee and hip osteoarthritis (OA) in a 26-week controlled clinical trial. Arthritis Rheumatism (1998) 41 (Suppl. 9):S83.
   Google Scholar
• •Evaluates efficacy of MK0966.
   Google Scholar
• LANZA F, SIMON T, QUAN H eta].: Selective inhibition of cyclooxygenase-2 (COX-2) with MK-0966 (250 mg qd) is associated with less gastroduodenal damage than aspirin (ASA) 650 mg qid or ibuprofen (IBU) 800 mg tid. Gastroenterology (1997)112:A194.
   Google Scholar
• BJARNASON I, SIGTHORSSEN G, CRANE R et al.: COX-2 specific inhibition with MK-0966 25 or 50 mg qd does not increase intestinal permeability: a controlled study with placebo and indomethacin 50 mg tid. Am. J. Gastroenterol. (1998) 93:A246.
   Google Scholar
• HUNT R, BOWEN B, JAMES C eta].: COX-2 specific inhibi-tion with MK-0966 25mg or 50mg qd over 4 weeks does not increase fecal blood loss: A controlled study with placebo and ibuprofen 800mg tid. Am. J. Gastroenterol (1998) 93:A247.
   Google Scholar
• LAINE LL, HAWKEY CJ, HARPER S et al.: Effect of the COX-2 specific inhibitor (C-250 Rofexicob on ulcer formation: A double blind comparision with ibuprofen and placebo. Gastroenterology (1999) 116(4) G0996.
   PubMedGoogle Scholar
• OSHIMA M, DINCHUK JE, KARGMAN SL et al.: Supression of intestinal polyposis in APC 716 knockout mice by inhibition of cyclooxygenase 2 (COX-2) . Cell (1996)87:803–809.
   PubMed Web of Science ®Google Scholar
• ••Key paper looking at importance of COX-2 in coloncarcinogenesis.
   Google Scholar
• EBERHART CE, COFFEY RJ, RADHIKA A, GIARDIELLO FM, FERRENBACH S, DUBOIS R: Up-regulation of Cyclooxy-genase 2 Gene Expression in Human Colorectal Adenomas and Adenocarcinomas. Gastroenterology (1994)107:1183–1188.
   PubMed Web of Science ®Google Scholar
• SHENG GC, SHAO J, SHENGE EB et al.: A Selective Cyclooxygenase 2 Inhibitor Suppresses the growth of H-Ras-Transformed Rat Intestinal Epithelial Cells. Gastroenterology (1997) 113: 1883-1891.
   Google Scholar
• TSUJII M, DU BOIS RN: Alterations in Cellular Adhesion and Apotosis in EpithelialCells overexpressing Prosta-glandin Endoperoxide Synthase 2. Cell (1995) 83:493–501.
   PubMed Web of Science ®Google Scholar
• SIMMONS DL, MADSEN ML, ROBERTSON PM: COX-2 andapoptosis: NSAIDS as effectors of programmed cell death. Selective COX-2 inhibitors. Pharmacology, Clinical effects and Therapeutic potential. (Chapter 5). Kluwer Academic Publishers, London, (1997):55–57.
   Google Scholar
• PIAZZA GA, KULCHAK RAL, KRUTCH M et al.: Anti neoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apotosis. Cancer Res. (1995) 55:3110–3116.
   PubMed Web of Science ®Google Scholar
• MAHMOUD NN, BOOLBOL SK, DANNENBERG SJ et al.:The sulfide metabolite of sulindac prevents tumors and restores enterocyte apotosis in a murine model of familial adenomatous polyposis. Carcinogenesis (1998) 19:87–91.
   PubMed Web of Science ®Google Scholar
• PIAZZA GA, ALBERTS DS, HIXSON L et al.: SulindacSulfone Inhibits Azoxymethane-Induced Colon Carcinogenesis in Rats Without Reducing Prosta-glandin Levels. Cancer Research (1997) 57:2909–2915.
   PubMed Web of Science ®Google Scholar
• HANIF R, PITTAS A, FENG Y et al.: Effects of non steroidalanti-inflammatory drugs on proliferation and induction of apotosis in colon cancer cell lines by prostaglandin independant pathways. Biochem. Pharmacol. (1996) 52:237–245.
   PubMed Web of Science ®Google Scholar
• ELDER DJE, HAGUE A, HICKS DJ, PARASKEVA C: Differ-ential growth inhibition by aspirin metabolite salicy-late in human colorectal tumour cell lines: Enhanced apotosis in carcinoma and in in-vitro -transformed adenoma relative to adenoma cell lines. Cancer Res. (1996) 56:2273–2276.
   PubMed Web of Science ®Google Scholar
• TSUJJI M, KAWANO S, TSUJII S, SAWAOKA H, HORI M,DUBOIS RN: Cyclooxygenase regulates angiogensis induced by colon cancer cell lines. Cell (1998) 93:705–716.
   PubMed Web of Science ®Google Scholar
• JACKSON LM, WU KC, MAHIDA YR, JENKINS D, HAWKEY CJ: COX-1 expression in human gastric mucosa infected with Helicobacter pylori: constitutive or induced? Gastroenterology (1998) 114:A160.
   Web of Science ®Google Scholar
• MIZUNO H, SAKAMOTO C, MATSUDA K et al.: Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice. Gastroenterology (1997) 112:387–397.
   PubMed Web of Science ®Google Scholar
• SCHMASSMAN A, PESKAR BM, STETTLER C et al.: Effects of inhibition of prostaglandin endoperoxide synthase-2 in chronic gastro-intestinal ulcer models in rats. Br. J. Pharmacol. (1998) 123:795–804.
   PubMed Web of Science ®Google Scholar
• ••Addresses the potential importance of COX-2 in the GI tract.
   Google Scholar